Dual-targeting prodrug nanotheranostics for NIR-Ⅱ fluorescence imaging-guided photo-immunotherapy of glioblastoma

• DOI: 10.1016/j.apsb.2022.05.016
• Publication Date: 2022-05-20T03:39:23Z
• Authors: Fenglin Li; Yi Lai; Jiayi Ye; Madiha Saeed; Yijing Dang; Zhifeng Zou; Fangmin Chen; Wen Zhang; Zhiai Xu
• Keywords: 0301 basic medicine; Precise immunotherapy; 0303 health sciences; 03 medical and health sciences; NIR-II fluorescence imaging; Original Article; Therapeutics. Pharmacology; RM1-950; Glioblastoma; Dual targeting; Photothermal therapy; 3. Good health

Glioblastoma (GBM) therapy is severely impaired by the blood-brain barrier (BBB) and invasive tumor growth in central nervous system. To improve GBM therapy, we herein presented a dual-targeting nanotheranostic for second near-infrared (NIR-II) fluorescence imaging-guided photo-immunotherapy. Firstly, NIR-Ⅱ fluorophore MRP bearing donor-acceptor-donor (D-A-D) backbone was synthesized. Then, prodrug nanotheranostics were prepared self-assembling with of JQ1 (JPC) T7 ligand-modified PEG5k-DSPE. can cross BBB tumor-targeted delivery JPC MRP. could be restored from at site suppressing interferon gamma-inducible programmed death ligand 1 expression cells. generate NIR-II to navigate 808 nm laser, induce photothermal effect trigger in-situ antigen release site, ultimately elicit antitumor immunogenicity. Photo-immunotherapy dual-loaded nanoparticles remarkably inhibited vivo. The might represent novel nanoplatform precise photo-immunotherapy GBM.